الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 279 |  |  |
| | | from | 279 | | |
Abstract
Tuberculosis treatment strategy includes standard short course of drugs delivery, lasting 6 months for newly diagnosed patients and 8 months for relapsed patients. DM may passively influence the achievement of WHO ambitious target for TB management including reduction in TB incidence by 25% and mortality rate by 75% respectively in 2025 and affecting on the pharmacokinetic of anti-TB agents.
Therefore, a systematic review and meta-analysis study was conducted for revealing the effect of diabetes mellitus on pharmacokinetics of anti-tuberculosis drugs (isoniazid and rifampicin). Moreover, an experimental study was performed for evaluating of pharmacodynamic effects of anti-tuberculosis drugs (isoniazid and rifampicin) in diabetic rats.